Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971
Alan S. Gamis(Children's Mercy Hospital), Franklin O. Smith(Cincinnati Children's Hospital Medical Center), Mukta Sharma(Children's Mercy Hospital), Robert B. Gerbing(Arcadia), Gita Massey(Virginia Commonwealth University), Yaddanapudi Ravindranath(Wayne State University), Todd A. Alonzo(University of Southern California), April Sorrell(City of Hope), John P. Perentesis(Cincinnati Children's Hospital Medical Center), John Doyle(Hospital for Sick Children), Joanne M. Hilden(Children's Hospital Colorado), Dorothy Barnard(Izaak Walton Killam Health Centre), Thomas Loew(University of Missouri), R.J. Arceci(University of Arizona), Jeffrey W. Taub(The Barbara Ann Karmanos Cancer Institute)
Cited by 230
Related Papers
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases
|JAMA Oncology|2022|557
The multidrug resistance (mdr1) gene product functions as an ATP channel.
|Proceedings of the National Academy of Sciences|1993|372
Renal Carcinomas With the t(6;11)(p21;q12)
|The American Journal of Surgical Pathology|2005|290
Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
|Journal of Clinical Oncology|2012|231